What Happened?
Philadelphia, PA-based Century-Therapeutics Promoted Michael Diem as Chief Financial Officer
About the Company
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
About the Person
Michael Diem is Chief Financial Officer at Century Therapeutics. Previously, Michael held various senior HR leadership roles in the industry.
Info Source
News
Short Profile